Global PharmaSphere: Emerging Biotechnologies-Gene Therapy market 2017 Research Report offers a replete and diligent analysis of the growth rate of the PharmaSphere: Emerging Biotechnologies-Gene Therapy industry.This report scrutinize current market trends, future growth potential, dominant market growth drivers, elements impeding market growth, opportunities, market framework, market challenges, market future prognosis and best practices in the global PharmaSphere: Emerging Biotechnologies-Gene Therapy market.

Report Synopsis:

Initially, the research study provides subtle knowledge of the PharmaSphere: Emerging Biotechnologies-Gene Therapy market composition, evaluates and overviews its multifaceted aspects & applications. It formulate both its quantitative and qualitative patterns of investigative research. The research study split the global PharmaSphere: Emerging Biotechnologies-Gene Therapy market on the basis of different parameters and assesses each section as well as sub-section of PharmaSphere: Emerging Biotechnologies-Gene Therapy market.

Do Inquiry Before Purchasing Report Here:https://market.biz/report/global-pharmasphere-emerging-biotechnologies-gene-therapy-market-icrw/42494/#inquiry

The major areas on which the report focuses on related to each firm are key competitor profile overview/description, fiscal & accounting details, business strategies and recent developments.

Key Dominant players in PharmaSphere: Emerging Biotechnologies-Gene Therapy market:

1 Dimension Therapeutics 2 Celladon Corporation 3 Bluebird bio 4 Avalanche 5 AskBio 6 Applied Genetic Technologies Corporation 7 AnGes MG, Inc. 8 American Gene Technologies International Inc 9 Amarna Therapeutics 10Advantagene

The report also scrutinates market growth potential, market scope and sales prophecy across different regions.

Region Based Analysis of PharmaSphere: Emerging Biotechnologies-Gene Therapy Market:

1 USA 2 South East Asia 3 India 4 Europe 5 China

Get Sample Copy Of Report From Here: https://market.biz/report/global-pharmasphere-emerging-biotechnologies-gene-therapy-market-icrw/42494/#requestforsample

Global PharmaSphere: Emerging Biotechnologies-Gene Therapy market is Splited into two segments product and application.

In addition,the elements that triggers and restrict the growth of the global PharmaSphere: Emerging Biotechnologies-Gene Therapy industry are mentioned and clarified in depth in this research study. It assists professionals in taking crucial business decisions to publicize their business. The study also scrutinize areas having potentialities for future market growth. It also provides information about emerging markets, profitable markets, static markets, declining markets, saturated markets or mature markets along with growth benefits.

Overall the PharmaSphere: Emerging Biotechnologies-Gene Therapy report offers complete substantial analysis of the parent market, key strategies followed by dominant industry Players, forthcoming segments, former, current and forecast market analysis in terms of volume and value along with entire research conclusions.

The Report serves as a valuable/profitable guide for the industry players and other individuals who are interested in studying the PharmaSphere: Emerging

Biotechnologies-Gene Therapy market.

For More chemicals Research Reports Visit : http://assetsstock.com/category/chemicals

Divyang has been into market research industry for last 5 years. He has a keen interest and deep knowledge of research industry. He has a stint of experience working as Research Analyst. His goals in life are simple - to stay happy, healthy and to keep writing as long as she possibly can.

View post:
Global PharmaSphere: Emerging Biotechnologies-Gene Therapy Market - Assets Stock

Recommendation and review posted by sam

May 04, 2017 16:06 ET | Source: REGENXBIO Inc.

ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced that preclinical data from studies supported byREGENXBIOat the University of Pennsylvanias Gene Therapy Program and Center for Advanced Retinal and Ocular Therapeutics and at the Johns Hopkins Wilmer Eye Institute will be shared in one presentation and four posters at upcoming conferences including the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology (ARVO), and the American Society of Gene and Cell Therapy(ASGCT). These data support further clinical research regarding the use of REGENXBIOs investigational gene therapy RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).

RGX-314 has the potential to be a one-time treatment for people with wet AMD by delivering high expression of anti-VEGF antibodies through the use of our NAV AAV8 vector.We are pleased to share additional positive preclinical results, which were generated by our development partners at the University of Pennsylvania and Johns Hopkins, which support our active IND, said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. REGENXBIOis on track to begin enrollment in the RGX-314 Phase I clinical trial by mid-2017 and to provide an interim trial update by the end of 2017.

Details of the upcoming presentation and posters are as follows:

Presentation at Retinal Cell and Gene Therapy Innovation Summit

Title:Preclinical gene therapy studies to select RGX-314 doses to treat wet age-related macular degeneration Presenter:Jean Bennett, PhD, Department of Ophthalmology,University of Pennsylvania,Philadelphia, PA Session date/time:Friday, May 5, 9:20 a.m. 9:30 a.m. EDT Session title:Gene Therapy, Outcome Measures, and Novel Therapies, Session 1: Preclinical Aspects Vector Design/Animal Models Room:Holiday 1-3, Hilton Baltimore, Baltimore, MD

Posters at Association for Research in Vision and Ophthalmology

Title:RGX-314, an AAV8 expressing an anti-VEGF protein, strongly suppresses subretinal neovascularization and vascular leakage in mouse models Authors:Ji-kui Shen1, Yuanyuan Liu1, Seth D. Fortmann1, Stephen Yoo3, Karen Kozarsky2, Jiangxia Wang1, Peter A. Campochiaro1. 1Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States; 3REGENXBIO Inc, Rockville, Maryland, United States Session date/time:Sunday, May 7, 8:30 a.m. 10:15 a.m. EDT Session title:Cytokines; Growth factors; Antiangiogenic drugs Room:Exhibit/Poster Hall, Baltimore Convention Center, Baltimore, MD Abstract number:B0230

Title: Subretinal delivery of RGX-314 AAV8-anti-VEGF Fab gene therapy in NHP Authors: Anna Tretiakova1, Tomas S. Aleman3, Arkady Lyubarsky3, Elaine J. Zhou4, Erik Wielechowski1, Gui-Shuang Ying2, Erin Bote1, Leah Makaron1, Stephen Yoo5, Jean Bennett3,6, Albert M. Maguire3,6, James Wilson1. 1Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States;2Center for Preventative Ophthalmology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, United States;3Center for Advanced Retinal and Ocular Therapeutics, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States;4Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States;5REGENXBIO, Rockville, Maryland, United States;6Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States Session date/times:Wednesday, May 10, 11:00 a.m. 12:45 p.m. EDT Session title:Gene editing and gene therapies Room:Exhibit/Poster Hall, Baltimore Convention Center, Baltimore, MD Abstract number: B0164

Title: Normal parameters of the full field ERG recorded with bipolar electrodes in Cynomolgus Macaque (Macaque fascicularis) Authors: Arkady Lyubarsky1,2, Erik Wielechowski3, Tomas S. Aleman4, Albert M. Maguire1,4, Gui-Shuang Ying4, Erin Bote3, Leah Makaron3, James Wilson3, Jean Bennett1,4, Anna P. Tretiakova3. 1Center for Advanced Retinal and Ophthalmic Therapeutics, SOM Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States;2Vision Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States;3Gene Therapy Program, University of Pennsylvania SOM, Philadelphia, Pennsylvania, United States;4Scheie Eye Institute, University of Pennsylvania SOM Ophthalmology, Philadelphia, Pennsylvania, United States Session date/times: Thursday, May 11, 8:30 a.m. 10:15 a.m. EDT Session title: Retinal Function ERG studies Room: Exhibit/Poster Hall, Baltimore Convention Center, Baltimore, MD Abstract number: B0441

Additional information on the meeting can be found on the ARVO website:http://www.arvo.org

Poster at American Society of Gene and Cell Therapy

Title:Safety of RGX-314 AAV8-anti-VEGF Fab Gene Therapy in NHP Following Subretinal Delivery Authors:Tomas S. Aleman1, Anna P. Tretiakova2, Arkady L. Lyubarsky1, Jessica I. W. Morgan2, Elaine J. Zhou3, Erik Wielechowski2, Gui-Shuang Ying4, Erin Bote2, Leah Makaron2, Stephen Yoo5, Jean Bennett1, Albert M. Maguire1, James M. Wilson2. 1Center for Advanced Retinal and Ocular Therapeutics, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA,2Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA,3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,4Center for Preventative Ophthalmology and Biostatistics, University of Pennsylvania, Philadelphia, PA,5REGENXBIO, Rockville, MD. Session date/times:Thursday, May 11, 5:15 p.m. 7:15 p.m. EDT Session title:Neurologic Diseases (including Ophthalmic and Auditory Diseases) II Room:Exhibit Hall A & B South, Marriot Wardham Park Hotel, Washington, DC Abstract number:427

Additional information on the meeting can be found on the ASGCT website:http://www.asgct.org

Note Regarding Penn

Penn has licensed certain Penn-owned AAV intellectual property to REGENXBIO, including rights related to RGX-314.Dr. Wilson is an advisor to REGENXBIO and is a founder of, holds equity in, and receives sponsored research support from REGENXBIO.

AboutREGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIOs NAVTechnology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, REGENXBIOs research, development and regulatory plans in connection with its NAV Technology Platform and gene therapy treatments. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could cause actual results to differ materially from those projected by such forward-looking statements. All of REGENXBIOs development timelines could be subject to adjustment depending on recruitment rate, regulatory agency review and other factors that could delay the initiation and completion of clinical trials. Meaningful factors which could cause actual results to differ include, but are not limited to, the timing of enrollment, commencement and completion of REGENXBIOs clinical trials; the timing and success of preclinical studies and clinical trials conducted by REGENXBIO and its development partners; the ability to obtain and maintain regulatory approval of REGENXBIOs product candidates and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing REGENXBIOs product candidates; REGENXBIOs ability to obtain and maintain intellectual property protection for REGENXBIOs product candidates and technology; REGENXBIOs growth strategies; REGENXBIOs competition; trends and challenges in REGENXBIOs business and the markets in which REGENXBIO operates; REGENXBIOs ability to attract or retain key personnel; the size and growth of the potential markets for REGENXBIOs product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of REGENXBIOs product candidates; REGENXBIOs ability to establish and maintain development partnerships; REGENXBIOs expenses and revenue; regulatory developments in the United States and foreign countries; the sufficiency of REGENXBIOs cash resources and needs for additional financing; and other factors discussed in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of REGENXBIOs Annual Report on Form 10-K for the year ended December31, 2016. In addition to the risks described above and in REGENXBIOs filings with the Securities and Exchange Commission, other unknown or unpredictable factors also could affect REGENXBIOs results. There can be no assurance that the actual results or developments anticipated by REGENXBIO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, REGENXBIO. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. REGENXBIO cautions investors not to rely too heavily on the forward-looking statements REGENXBIO makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). REGENXBIO undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Related Articles

Original post:
Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be ... - GlobeNewswire (press release)

Recommendation and review posted by sam

Cell-based therapeutics developer ReNeuron Group announced on Friday that it would be presenting new data relating to the characterisation and scale-up of its CTX cell-derived exosome therapy candidates at a leading scientific conference in London, also on Friday.

The AIM-traded firm explained that, in a poster presentation, ReNeuron researchers and their academic collaborators at the Department of Biochemical Engineering, University College London, would address the challenges of purifying CTX-derived exosomes at scale whilst preserving their potential therapeutic attributes to ensure consistency of future manufacture.

New strategies were being presented to address the upstream cell culture processes needed to generate the exosomes and the downstream purification methods that could be applied to remove protein and DNA-based impurities from the exosomes at commercially relevant scale.

The new methods yielded a threefold increase in particle protein purity and a more than fivefold increase in particle DNA purity compared with previous purification processes.

In a further poster presentation, research teams at ReNeuron and at the UK's Cell and Gene Therapy Catapult would address the challenge of characterising ReNeuron's CTX cell-derived exosomes to ensure consistency and control during manufacture.

The company said the studies undertaken demonstrated a robust approach to optimising and qualifying assays for micro-RNA (miRNA) targets found in the exosomes.

A potential advantage of exosomes when utilised as a carrier for the delivery of therapeutic miRNAs in gene therapy was the avoidance of issues typically encountered by RNA-based drugs, such as stability in vivo and tissue targeting, ReNeurons board explained.

The application of robust characterisation and purification methods to ReNeuron's exosome populations would support the future development of the company's exosome-based therapeutic candidates across multiple potential disease indications - the initial disease target being cancer.

The data being presented at the ISCT 2017 conference represent key advances in the development of ReNeuron's CTX-derived exosome therapeutic programme, both as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments, said ReNeurons head of research Randolph Corteling.

We look forward to presenting further data from this programme in the months ahead, Dr Corteling added.

See the original post here:
ReNeuron presenting new data on Friday - DIGITALLOOK

Recommendation and review posted by sam

Californias stem cell agency is on the hunt for a new president and CEO after the surprise announcement this week that C. Randal Mills will be departing the California Institute for Regenerative Medicine. He will leave at the end of June.

Mills, who has headed the agency for three years, will become the next president and CEO of the National Marrow Donor Program. CIRM is replacing him on an interim basis with Maria Millan, M.D., the agencys vice president of therapeutics.

The state agency will soon begin a search for a permanent replacement, said Jonathan Thomas, CIRMs chairman. Millan is a candidate to fill that position, with Mills strong endorsement.

Mills is noted for reorganizing CIRM to provide greater systemic support for translating basic research into clinical science, and to provide quicker and more helpful responses to researchers seeking funding.

His initiative, called CIRM 2.0, was a response to criticism that the agency, funded with $3 billion in California bond money in 2004, has been too slow in getting treatments to patients. ($6 billion will be repaid, including $3 billion in interest)

Agency-supported treatments are now being tested in medical centers throughout the state, including San Diego County. Most prominently, CIRM has established an alpha stem cell clinic at UC San Diego. It is the cell therapy arm of UCSDs Sanford Stem Cell Clinical Center.

Mills said he decided to leave because the National Marrow Donor Program, which he was familiar with, resonated with his own goals of making personal connections with patients.

Before joining CIRM in 2014, Mills was president and CEO of Osiris Therapeutics, developer of a pediatric stem cell drug called Prochymal, used to treat a complication of bone marrow transplants called graft vs. host disease.

If you look at my office, the walls are covered with pictures of the children that we treated who went through bone marrow transplantation, Mills said. Getting to know them, and getting to know their families that had a tremendous effect.

The unexpected announcement drew surprise and concern from stem cell researchers and observers. As admirers of CIRM 2.0, they expressed uncertainty about what direction the agency would take. And with the $3 billion beginning to run out, looking for a new source of funding will be a top concern of Mills successor.

Confidence

But Mills said Wednesday the agency will do well.

If me leaving CIRM is a problem, then I didnt do a good job at CIRM, Mills said. Whether its because Im going to be the head of the National Marrow Donor Program or I get hit by a car, the success of this organization, or any organization thats healthy and functional, should never pivot on one person, Mills said. Ive assembled a team at CIRM that I have absolute, absolute confidence in.

Mills said he would be surprised if Millan didnt turn out to be the agency boards overwhelming choice to be his permanent successor. She assisted in developing the agencys strategic plan and helped it run smoothly, he said.

In 2015, Mills named Millan as senior director of medical affairs and stem cell centers, one of three appointments to CIRMs leadership team. Before joining CIRM, she was vice president and acting chief medical officer at StemCells, Inc. Before that, Millan was director of the Pediatric Liver and Kidney Transplant Program at Stanford University School of Medicine.

Millan said the agencys strategic plan is working, and taking the agency where it needs to go. That plan was developed to guide researchers, doctors and companies over the predictable hurdles they encounter in translating basic research into therapies testable in the clinic and that companies would want to commercialize.

Weve already done the challenging piece of identifying the how how to get to the mission, which is to accelerate these stem cell treatments to those with unmet medical needs, Millan said. Team members are all aligned in accomplishing these goals One cant help but be more energized and motivated to execute on the strategic plan.

About 30 stem cell clinical trials are under way that the agency has funded at one stage or another in research and development.

Jonathan Thomas, the CIRM chairman, said Mills has done what he promised when joining CIRM, and the agency is operating markedly better, in productivity, speed and efficiency.

He has made it, through CIRM 2.0 and beyond, a humming machine that is operating on all cylinders, Thomas said. In doing that, hes worked extensively and highly collaboratively with Maria (Millan) and the rest of the team. That has made CIRM an even better operation than it ever was. So we are in extremely good shape right now to go forward.

Goals accomplished

Jeanne Loring, a CIRM-funded stem cell scientist at The Scripps Research Institute, said Mills made the agency friendlier and more predictable for the scientists it funds.

The first and most dramatic thing he did was to end the process of independent grants, Loring said. Under that process, each grant proposal was considered on its own, with no consideration for success under a previous grant for an earlier stage of the research.

It was always very troubling to people, I think, that they could do very well with CIRM money on an early-stage grant, and that would earn them nothing in a further application to continue the work, Loring said.

As part of CIRM 2.0, Mills emphasized that once projects were accepted for funding, CIRM would become a partner with the scientists to help them accelerate research and development, and ultimately commercialization.

Loring leads a team researching the use of stem cells for Parkinsons therapy. The cells are collected from the patients to be treated, making them a genetic match. They are then genetically reprogrammed to resemble embryonic stem cells, and then matured into the brain cells destroyed in Parkinsons.

Lorings team was awarded $2.4 million in 2016 from CIRM to advance its research. A next-stage grant to translate the research to a clinically ready approach would need about $7 million, Loring said. The work is part of Summit for Stem Cell, a nonprofit alliance of scientists, doctors, patients and Parkinsons disease community supporters.

Veteran stem cell watcher David Jensen praised Mills on his blog, California Stem Cell Report.

"Dr. Mills made substantial contributions to the agency during his tenure, improving both efficiency of the grant making process and transparency of CIRM's operations, Jensen quoted stem cell observer John M. Simpson of Consumer Watchdog as saying.

Simpson added that as CIRM draws down the rest of its $3 billion with no new funding in sight, its not surprising that Mills would accept another job.

Paul Knoepfler, a CIRM-funded stem cell scientist and blogger, wrote Tuesday that Mills had a big positive impact on CIRM and helped it go to the next level.

About the only thing I wasnt a fan of in terms of his leadership was my perception of his negativity toward the FDA and toward FDA oversight of stem cells, and how that manifested at CIRM during his time there, Knoepfler wrote. But good people can strongly disagree on policy.

bradley.fikes@sduniontribune.com

(619) 293-1020

UPDATES:

8:50 a.m.: This article was updated with additional details.

This article was originally published at 2:30 p.m., May 3.

See the article here:
Amid uncertain future, California's stem cell agency loses transformative leader - The San Diego Union-Tribune

Recommendation and review posted by Bethany Smith

The Lehigh football team hosted a bone marrow drive in Lamberton Hallon April 27.

The drive, Be the Match,is a nationwide registry that started at Lehigh in 2009 when Andy Talley, the head football coach at Villanova, reached out to Lehighs head coach Donnie Roberts and asked if he would be interested in contributing to the bone marrow drive.

Roberts said he tries to have more students attend every year and join the cause. Each year, the team strives to get as many students to sign up because the chances of finding a perfect bone marrow match are slim. Since 2009, seven Lehigh students have been perfect matches, four of them football players. Roberts saidthe first student who donated in 2011 ended up having a relationship with the person he donated to.

Yales been (registering) over 400 people every year since theyve been involved, Roberts said. Were not even close to that. But its just the idea that here at Lehigh, if were over 100, I feel good. If we were one, I would feel good, because this is bigger than sports when you have the opportunity to save someones life.

Dan Scassera, 19, left, and Tyler Cavenas, 18, help, from left, Tyler Monaco, 20, Yannick Gbadouwey, 18, and Ben Pingrey, 17, fill out their bone marrow donation forms Thursday, April 27, 2017, in Lamberton Hall. To help donors make a decision, Scassera and Cavenas explain what happens if they are a match. (Roshan Giyanani/B&W Staff)

Participants remain on the registry until their 61st birthday unless they request to be removed from future searches for a match, or they do not meet medical requirements to be eligible. While it is a long-term commitment, Be the Match does its bestto cover all medical and travel costs of donating.

Assistant coach Tyler Ward, 14,said applicants fill out a form, their cheeks are swabbed to retrieve DNA and the samples are sent out to be analyzed.

I think one out of 432 people end up matching with someone, which is why we need so many more people to sign up, Wardsaid.

If applicants are matched with someone, they receive a phone call andgo to a nearby doctor to learn how they can donate. There are two different ways to donate,either through giving blood or bone marrow.

Giving bone marrow is similar to giving blood. Eighty percent ofpeople who donate at all donate blood while 20 percent donate bone marrow. Blood donations are processed through a machine that removes stem cellsand returns blood to the system. Bone marrow donations involve a surgery under anesthesia where marrow is removed from the pelvic bone.Ward saidboth procedures are minor.

At the last station, students are given the option to discreetly remove their consent. This allowed students to decide whether or not they wanted to continue with the donor process. (Roshan Giyanani/B&W Staff)

You dont feel it, youre under anesthesia, and both of them are pretty quick, pretty seamless processes, Ward said.

Roberts said after having the marrow removed, he foundthe pain comparable to lightly bruising a hip. He said whilethe thought of going under anesthesia and having a procedure done is intimidating, it could save someones life.

Julia Wise, 20, helped students with forms at the drive.

I think this is an awesome event, especially on a college campus, because you can recruit so many more people, Wise said. The youngest generation is whats really going to help this cause.

Read more:
Football team hosts 'Be the Match' bone marrow drive - The Brown and White

Recommendation and review posted by simmons

Xconomy Boston

Magenta Therapeutics said today it has doubled its money with a $50 million Series B round led by GV, formerly Google Ventures. The Cambridge, MA-based startup spun out of Harvard University last year with nearly $50 million in launch money to develop improved bone marrow transplants.

Magenta has also licensed a drug from Novartis that it says could help boost the number of healthy stem cells that are delivered into a patients body, a key procedure in a transplant.

Used to treat people with cancer and other blood-borne diseases, a bone marrow transplant starts with a procedure to kill a patients diseased blood stem cells, which live in the bone marrow. The diseased cells are then replaced with healthy stem cells, usually from a donor. Though growing safer, its still a risky process, especially for elderly or frail patients. Deaths related to the treatment have dropped below 20 percent in recent years, but Magentas founders as well as researchers at Stanford University are among the groups working to improve the complicated steps.

Magenta is developing three types of drugs, each for a different procedure in the transplant process. It will test them as separate products but try to market them as a suite to transplant clinics, according to management.

The drug Magenta licensed from Novartis is applied to cells from donated umbilical cord blood, which have different properties than cells from blood donated by adults. The drug, which recently completed an early stage study, is meant to stimulate the blood cells to replicate faster outside the body, providing a bigger population to put back into the patient. The more cells, the better the chance that the new healthy cells will engraft, or survive in the patients bone marrow.

Magenta also aims to develop an alternative to chemotherapy or radiation, which a patient receives before a transplant to kill his or her diseased stem cells; and a treatment to coax an adult donors stem cells out of the bone marrow and into the bloodstream, where the cells are easier to harvest for the transplant.

Other investors in the new round are previous backers Third Rock Ventures, Atlas Venture, Partners Innovation Fund, and Access Industries, and new investors including Casdin Capital and BeTheMatch BioTherapies, which is affiliated with the nonprofit international bone marrow registry NMDP/Be The Match.

Magenta said it would work with BeTheMatch BioTherapies on research and development.

Photo Bone Marrow Donation by Andrew Ratto via a Creative Commons 2.0 license.

Alex Lash is Xconomy's National Biotech Editor. He is based in San Francisco.

Follow this link:
Magenta Nabs More Cash, Licenses Drug To Boost Transplant ... - Xconomy

Recommendation and review posted by sam

Ive been a fan of stem cells ever since I discovered ReLuma and AQ Skin Solutions, both of which use human conditioned media from adult adipose fat. Back then, it was a leap of face based on research surrounding stem cells and wound healing. Ever since, I have relied on my own experience and reports from the Truth In Aging community stem cells seem to work. So, I was excited (and vindicated) to read new research on stem cells and aging.

Researchers from the Perelman School of Medicine at the University of Pennsylvania found adult stem cells collected from human fat have a potential use to treat aging. Their findings are published in the journal, Stem Cells. The posh name for fat is adipose (worth keeping in mind if you want to bewilder a loved one by asking them if your bottom looks adipose in these pants). Anyway, adipose-derived stem cells (ASCs), create more proteins than researchers initially thought even when harvested from the elderly.

Our study shows these cells are very robust, even when they are collected from older patients, said Ivona Percec, M.D., director of Basic Science Research in the Center for Human Appearance and the study's lead author. It also shows these cells can be potentially used safely in the future because they require minimal manipulation and maintenance. Now, notice Dr. Percec uses the word safely. This is also a useful development, because we have never really known whether administering stem cells as anti-agers was really a safe thing to do.

Interestingly, adipose stem cells behave differently to other stem cells such as fibroblasts from the skin in that they are more stable over time and the rate at which they multiply stays consistent even as we age. I found some research from 2013 that speculated that these cells may be the same in infants through to the elderly. Dr. Perecs research seems to have clinched that this is indeed the case.

When you harvest adipose derived stem cells, they can become virtually any type of cell and put to the service of anti-aging, as well as healing purposes. Recent research has shown that they are a powerful source of skin regeneration because of their capability to provide not just cells but also tons of cytokines, or growth factors. The result, as one research paper puts it, is great promise for applications in repair of skin, rejuvenation of aging skin and aging-related skin lesions.

Adipose stem cells were discovered 40 years after the identification of bone marrow stem cells, opening up a new era of active stem cell therapy. It looks as if we are on the threshold of much more discovery in this field. For instance, Dr. Percec and her team are taking the research a step further to look at how tight the DNA is wound around proteins inside the cells and the way this affects aging.

More:
New Study Finds Human Fat Has Potential to Treat Aging - Truth In Aging

Recommendation and review posted by simmons

Science Daily

Scientists turn human induced pluripotent stem cells into lung cells ... Science Daily Scientists have announced two major findings that further our understanding of how stem cells become organs: the ability to grow and purify the earliest lung ... and more »

Read this article:
Scientists turn human induced pluripotent stem cells into lung cells ... - Science Daily

Recommendation and review posted by simmons

CAMBRIDGE, Mass. and CROMWELL, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific models for challenging diseases, and Biological Industries USA (BI-USA), a subsidiary of Biological Industries (Israel), today announced a new sales and marketing agreement to promote custom stem cell services. The partnership combines BI-USAs strength in stem cell culture media and manufacturing with Cellarias comprehensive Stem Cell Services program, which includes industry leading RNA reprogramming and custom differentiation services. Together, the companies will offer one of the industrys most innovative and comprehensive stem cell service offerings available to biotechnology companies and academic institutions.

As part of the agreement, Cellaria will distribute BI-USAs stem cell media offering, including its NutriStem hPSC Medium, a cGMP xeno-free media specifically designed for human pluripotent stem cell culture. Cellaria will also incorporate the product into its stem cell services. BI-USA will market Cellaria's customized stem cell services, establishing an integrated, single source solution for iPS cell line derivation, culture maintenance, banking, characterization and differentiation services.

BI is one of the most respected names in life sciences today, said David Deems, chief executive officer at Cellaria. The companys strong market presence and innovative media products will enhance our stem cell and RNA reprogramming service offerings and significantly increase the availability and appeal of our combined offerings.

This is an important partnership for us, added Tanya Potcova, chief executive officer of BI-USA. In combination, our teams bring a wealth of stem cell experience but also share a common goal of creating higher quality, more consistent research outcomes for researchers in the life sciences field. We are pleased to be working with the team at Cellaria to put the best possible tools and support in the hands of our present and future customers.

Please visit Cellaria and BI at the International Society of Stem Cell Research Annual Meeting in Boston, MA June 14-17, 2017 at booth# 407.

About Cellaria Cellaria creates high quality, next generation in vitro disease models that reflect the unique nature of a patients biology. All models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellarias cell models exhibit molecular and phenotypic characteristics that are highly concordant to the patient. For RNA-mediated iPS cell line derivation and stem cell services, Cellarias cell models enable interrogation of patient and disease-specific mechanisms of action. Cellarias innovative products and services help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure. For more information, visitwww.cellariabio.com.

About Biological Industries Biological Industries (BI) is one of the worlds leading and trusted suppliers to the life sciences industry, with over 35 years experience in cell culture media development and cGMP manufacturing. BIs products range from classical cell culture media to supplements and reagents for stem cell research and potential cell therapy applications, to serum-free, xeno-free media. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.

Biological Industries USA (BI-USA) is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share a history and expertise of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine. For more information, visit http://www.bioind.com or connect onLinkedIn,Twitter, andFacebook.

Visit link:
Cellaria and Biological Industries USA Partner on Stem Cell Media ... - Yahoo Finance

Recommendation and review posted by Bethany Smith

Colorado State University is one of multiple research institutions that uses stem cells from aborted fetal tissue to research HIV and AIDS, a practice some say is unnecessary and immoral, but researchers say is essential.

Emily Faulkner, a senior biology major at CSU and founder of the anti-abortion group, CSU Students for Life, has been advocating against the Universitys use of fetal tissue for moral and legal reasons. Faulkner believes the University has illegally obtained fetal tissue for research and still could be after similar allegations against Planned Parenthood and CSU arose in 2015.

Earlier this semester, Faulkner hung posters that said CSU buys trafficked baby parts but says they were ripped down an hour later.

For a community that expresses tolerance for (many other communities) it seems to be very intolerant of the pro-life community, Faulkner said. Its really hard to open peoples minds to actually see whats going on, especially when theres so much intolerance.

In January, a Republican panel from the House of Representatives released a report suggesting some Planned Parenthood clinics and firms sold fetal tissue for profit, which is illegal under federal law. The report concluded over a year-long investigation after similar allegations against Planned Parenthood arose in 2015.

The report cited documents indicating the University paid the tissue procurement organizations StemExpress and Advanced Bioscience Resources $2,000 and $100,000, respectively, for fetal tissue between 2010 and 2015. It is illegal to buy fetal tissue, but federal law does not specify how much can be charged for shipping and handling. The report questions whether or not ABR and StemExpress donated the fetal tissue or sold it for profit.

Faulkner brought up CSUs use of fetal tissue this semester in response to the report. She and CSU Students for Life collected signatures on a petition that asked CSU President Tony Frank to investigate whether or not CSU was involved in illegal obtainment of fetal tissue and to acknowledge its use in research.

In response to the 2015 allegations, Frank wrote to Rep. Doug Lamborn stating that CSU was compliant with all state and federal laws in acquiring fetal tissue. According to Executive Director of Public Affairs and Communications, Mike Hooker, and the Vice President for Research, Alan Rudolph, the University has continued to follow the state and federal laws.

(Part of) my job as an institutional official is making sure that we sustain the highest standards for practice even beyond what the feds recommend, Rudolph said.

In addition to legal concerns, Faulkner also has moral concerns. She said that though abortion may be legal, that does not mean it is right. She expressed concern about fetal tissue and organs being harvested from late-term fetuses with beating hearts.

Its quite inhumane, Faulkner said. Were talking about actual human beings that have livers, brains and hearts. Theyre actually living, breathing beings.

Faulkner said fetal tissue should not be necessary for research on curing or preventing HIV and AIDS, as there is also gene replacement therapy, which takes HIV out of infected cells, and pre-exposure prophylaxis treatment, which consists of taking a pill daily to prevent HIV. Faulkner also said that researchers could use induced pluripotent stem cells (iPS cells) created from adult cells instead of stem cells from fetal tissue.

Pluripotent cells have the ability to become any cell in the body. However, according to Rudolph, iPS stem cells from adults cannot be used in CSUs research on curing and bettering HIV and AIDS, which is conducted by CSU virology professor Ramesh Akkina.

Fetal tissue research, especially the work that Ramesh does, cannot currently be done any other way, Rudolph said.

Akkina uses stem cells from fetal tissue to recreate human immune systems in mice, which Rudolph said are multicellular systems. Akkinas humanized mice can be used to study the effects of countermeasures, including therapeutics, antibodies, vaccines or biologics, on a human immune system meant to improve or cure HIV.

Rudolph said that while scientists are looking into how to conduct research on HIV and AIDS using iPS stem cells, the cells are more limited in their ability to create other types of cells than stem cells from fetal tissue are. He said that cells from fetal tissue are so far back in their development that they have the ability to create complex functions that are lost when cells become older. Cells are more pluripotent.

Faulkner said she hopes that scientists research and work with iPS stem cells.

The lives of those affected by HIV/AIDS are very important, but so are the lives of the unborn, Faulkner wrote in a message to the Collegian. We cannot forget equality for all.

Collegian reporter MQ Borocz can be reached at news@collegian.com or on Twitter @MQBorocz22.

See the rest here:
CSU's use of fetal tissue for HIV/AIDS research sparks controversy - Rocky Mountain Collegian

Recommendation and review posted by Bethany Smith

Details WhaTech Channel: Industrial Market Research Published: 04 May 2017 Submitted by John Vardon WhaTech Premium News from QY Research Groups Viewed: 14 times

This report studies the global Regenerative Medicine market, analyzes and researches the Regenerative Medicine development status and forecast in United States, EU, Japan, China, India and Southeast Asia.Learn details of the Size, Status and Forecast 2022

What is Regenerative Medicine?

Download Report atwww.qyresearchgroups.com/request-sample/339736

History

Applications

Report:www.qyresearchgroups.com/send-an-enquiry/339736

This report focuses on the top players in global market, like

.

Table of Contents

Global Regenerative Medicine Market Size, Status and Forecast 2022 1 Industry Overview of Regenerative Medicine 1.1 Regenerative Medicine Market Overview 1.1.1 Regenerative Medicine Product Scope 1.1.2 Market Status and Outlook 1.2 Global Regenerative Medicine Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Regenerative Medicine Market by Type 1.3.1 Cell Therapy 1.3.2 Tissue Engineering 1.3.3 Biomaterial 1.3.4 Others 1.4 Regenerative Medicine Market by End Users/Application 1.4.1 Dermatology 1.4.2 Cardiovascular 1.4.3 CNS

Report:www.qyresearchgroups.com/339736

1.4.4 Orthopedic 1.4.5 Others

2 Global Regenerative Medicine Competition Analysis by Players 2.1 Regenerative Medicine Market Size (Value) by Players (2016 and 2017) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles 3.1 Acelity 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Regenerative Medicine Revenue (Value) (2012-2017) 3.1.5 Recent Developments 3.2 DePuy Synthes 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Regenerative Medicine Revenue (Value) (2012-2017) 3.2.5 Recent Developments 3.3 Medtronic 3.3.1 Company Profile 3.3.2 Main Business/Business Overview

READ MORE atwww.qyresearchgroups.com/report/global-regenerative-medicine-market-size-status-and-forecast-2022

See the rest here:
Latest report on regenerative medicine market just published - WhaTech

Recommendation and review posted by Bethany Smith

A diagnostic test for detecting Zika with CRISPR. Image: Wyss Institute

The gene editing tool CRISPR could one day mean that we can simply edit away disease, blight and undesirable genetic traits. Now, its also gaining traction in another realm of medical technology: diagnosing disease.

On Thursday, researchers at UC Berkeley announced that theyve discovered ten new CRISPR enzymes that can potentially be used to diagnose diseases like Zika or dengue fever quickly and cheaply. The technology isnt ready for prime-time yet, but it could eventually allow clinics to test a sample of someones blood, saliva, or urine for many diseases at once.

Typically, when people talk about CRISPR, they are actually talking about CRISPR-Cas9. Thats the CRISPR programming paired with one specific enzyme (Cas9) thats used to DNA at precise locations. But there are a host of other enzymes out there that can be used as part of the CRISPR system, and all of them have different talents. The new enzymes that Berkeley researchers have discovered are all variants of the CRISPR protein Cas13a, and their speciality seems to be detecting specific sequences of RNA, including those from a virus.

In genetic engineering, CRISPR is used to home in precisely on a specific piece of DNA, cut it, and put it back together with the desired genetic code. Here, the same principle is at work. Only instead of sending CRISPR to sniff out a specific piece of DNA, it hunts for RNAthe carbon copy of DNA used to make proteinsassociated with a specific virus present in someones blood, urine, saliva or other bodily fluid contains. And if CRISPR detects the genetic markers of a pathogen, it can let researchers know by fluorescing. No glow means no virus.

This method would be fantastic for cheap, point-of-care initial testing, said Alexandra East-Seletsky, the lead author on the study in Molecular Cell and a post-doc in the Berkeley lab of Jennifer Doudna, one of the scientists who initially discovered CRISPR. The power of the system is flexibility and speed for targeting new sequences, making it ideal for use during an infectious disease outbreak, or other systems requiring fast development.

The work piggy backs off earlier work by both Berkeley and the Broad Institute. In September, Berkeley researchers reported the discovery of Cas13a and its ability to detected specific sequences of RNA. Last month, the Broad Institute reported that it had used Cas13a to develop a diagnostic tool that could detect Zika and other viruses. At the time, they said that their technique was not only small and portable, but could cost as little as 61 cents per test in the field. Such a tool might detect viral and bacterial diseases, as well as potentially cancer-causing mutations.

The new work essentially expands the tools available in the toolbox, allowing the CRISPR systems to detect more than one thing at once.

It allows you to test a control substrate and an unknown at the same time, or look for multiple disease-related sequences at once using the same starting material, said East-Seletsky. The possibilities are endless.

Developing cheap, bedside disease detection is a sort of Holy Grail of medicine. CRISPRs potential role here has received considerably less attention than its ability to edit genes, but it could wind up being equally significant.

Still, East-Seletsky said, Thursdays study is just a proof of concept. There is yet a lot of work to be done before there is actually a CRISPR-based diagnostic tool available to clinics.

See the original post here:

CRISPR Could Transform the Way We Diagnose Disease - Gizmodo

Recommendation and review posted by Bethany Smith

TechCrunch

Scientists have eliminated HIV in mice using CRISPR TechCrunch An important breakthrough has been made in the eradication of AIDs. Scientists have found they can successfully snip out the HIV virus from mouse cells using CRISPR/Cas9 technology. Right now patients with the deadly virus must use a toxic concoction ... CRISPR and the Dawn of the New Biotech RevolutionReason (blog) Researchers use gene editing to eliminate HIV infection in miceCBS News Closer to a cure: CRISPR cuts HIV from its cellular hideoutNew Atlas Genetic Engineering & Biotechnology News -Geek -ScienceDirect -Temple Health all 85 news articles »

Read more:

Scientists have eliminated HIV in mice using CRISPR - TechCrunch

Recommendation and review posted by simmons

May 04, 2017 08:00 ET | Source: CRISPR Therapeutics AG

BASEL, Switzerland and CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based therapeutics for patients with serious diseases, has promoted Dr. Samarth Kulkarni, Ph.D. to the role of President and Chief Business Officer of CRISPR Therapeutics Inc., as announced today by Dr. Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics.The new role reflects Dr. Kulkarnis increased responsibilities in leading the strategic direction of the company and overseeing its U.S. operations.Dr. Kulkarni will continue to lead strategy, business development, investor relations and external communications in his expanded role.

Over the past two years as Chief Business Officer, Dr. Kulkarni had a leading role in the establishment of its key collaborations with Vertex and Bayer, and played a major part in helping finance the companys operations through its IPO. Sam has played a pivotal role in enabling the rapid growth of the company, and we look forward to his continued leadership, said Dr. Rodger Novak. Additionally, as we rapidly move our lead programs to the clinic, we will look to further expand our senior management with leaders having deep expertise in later-stage clinical development and registration of breakthrough therapies.

CRISPR Therapeuticss lead program, which aims to provide a functional cure for beta thalassemia and sickle cell disease, is on track and the company is planning to file for a clinical trial authorization in Europe by the end of 2017. CRISPR Therapeutics Inc., is a wholly-owned subsidiary and base of R&D operations for CRISPR Therapeutics AG, parent company of the CRISPR group.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking Statement

Certain statements set forth in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development and the commercial potential of CRISPR/Cas-9 gene editing technologies.. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and conduct of preclinical and clinical studies for the companys product candidates; availability and timing of results from preclinical and clinical studies; whether results from a preclinical study or clinical trial will be predictive of future results in connection with future trials or use; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading Risk Factors in the companys annual report on Form 10-K, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SECs website at https://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release.

Related Articles

Basel, SWITZERLAND

CRISPR Therapeutics AG Logo

LOGO URL | Copy the link below

Formats available:

Excerpt from:

CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer ... - GlobeNewswire (press release)

Recommendation and review posted by simmons

The European Centre for Disease Prevention and Control (ECDC) released more information today about the do-it-yourself CRISPR (Cas 9) kits found to be contaminated with harmful bacteria, saying the risk of infection is low but does exist.

The kits were identified by the Bavarian Health and Food Safety Authority on Mar 24. As a result, the ECDC said Germany has halted all importation of the DIY Bacterial Gene Engineering CRISPR Kit, manufactured in the United States and sold on the Internet for $150.

The gene-editing kit is labeled as containing a harmless laboratory strain of Escherichia coli HME63, but tests on two kits ordered from the United States in November of 2016 and in March showed contamination with several pathogenic bacteria, including antibiotic-resistant bacteria.

The ECDC identified the pathogens as Klebsiella pneumoniae, Enterobacter, and Enterococcus faecalis, which belong to biological risk group 2. Biological risk group 2 pathogens require safety handling, including wearing personal protective equipment.

Despite the presence of risk group 2 pathogens, the ECDC identified the risk of infection for users of the kits as low "because the manipulation of the kit does not involve percutaneous injury-prone manipulations. However, infection resulting from the contamination of broken skin or mucous membranes may occur, even though the kit recommends and provides disposable gloves."

At-home CRISPR kits are targeted at hobbyists and "citizen" scientists who want to participate in at-home experiments with genetic engineering by making precision genome edits in bacteria. The kits have become popular in recent years, and The Odin, the company selling the kit identified by German health officials, currently has a waiting list of about a week.

Though the risk of infection is low, the ECDC said that the bacteria from the kits could invade a human gastrointestinal track. "Bacteria with resistance can persist for several months in the intestinal tract of asymptomatic carriers. If a carrier develops severe illness and requires antimicrobial treatment, there is a potential risk that the antibiotic-resistant bacteria proliferate and subsequently cause multidrug-resistant infection."

Finally, the ECDC said that users of the CRISPR kit should dispose of their material in a safe way, so as not to introduce the multidrug resistant-bacteria into the environment. The agency didn't specify steps for safe disposal.

See also:

May 3 ECDC risk assessment

May 3 ECDC news release

CRISPR kit Web site

Read the original post:

ECDC says risk from contaminated CRISPR kits low - CIDRAP

Recommendation and review posted by simmons

In 2012, Cal biochemistry and molecular biology professor Jennifer Doudna and microbiologist Emmanuelle Charpentier, now of the Max Planck Institute, changed the world. They invented CRISPR-Cas9, a gene editing tool

Then in 2013, MIT bioengineer Feng Zhang published a paper in the journal Science that outlined a CRISPR process specifically for eukaryotic cells, i.e., those from higher plants and animalsAt that point, the CRISPR saga bifurcated into two parts: the research narrative and the legal fight.

[Berkeley law professor Robert ]Merges set it up this way: UC maintains that it has never been determined who first developed eukaryotic CRISPR applications, that CRISPR basically uses the same process for viruses and eukaryotic cells, and that the February decision should be reversed. But the patent trial court found that there is no interference in fact, which in this case basically means the inventions are not the same, said Merges.

Its like Cal claims it invented cookies, and then Broad says it invented chocolate-chip cookies, he says. If Cals [pending] patent is verified and Broads also is upheld, you could end up with a situation where a biotech company would need licenses from both Cal and Broad for a CRISPR application. That kind of bundled license is very common in the world ofpatents.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: The Current CRISPR Patent Dispute, Explained

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Originally posted here:

What you need to know about the legal battle over CRISPR patents - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

French startup Vivet Therapeutics raised 37.5 million (about $41 million) in a Series A round of financing to support the development of gene therapies for rare inherited metabolic diseases. The firm was set up in 2016 to develop treatments based on adeno-associated virus (AAV) vector technology licensed exclusively from its close collaborator, the Fundacin para la Investigacin Mdica Aplicada (FIMA), at the Center for Applied Medical Research (CIMA) in Pamplona, Spain, and from Massachusetts Eye and Ear (MEE) in Boston.

Novartis Venture Fund and Columbus Venture Partners led the Series A investment round. Roche Venture Fund, HealthCap, Kurma Partners, and Ysios Capital also participated.Florent Gros, managing director at Novartis Venture Fund, commented, "We have searched extensively for next-generation AAV technologies and clinical applications. We are very excited by Vivet Therapeutics' clinical and commercial prospects; the company has outstanding management, assets, and capabilities."

Based in Paris, and with a wholly owned subsidiary in Spain, Vivetaims to develop gene therapies targeting disorders including Wilson disease, progressive familial intrahepatic cholestasis (PFIC), and citrullinemia.The firm is usinga novel, synthetic AAV, AAV-Anc80, to introduce genes into hepatocytes.Lead Wilson disease gene therapy program VTX801 comprises a truncated, functional version of the defective ATP7B gene, delivered directly into liver cells using the AAV vector technology. First-in-human trials with VTX801 are projected to start by the end of 2018.

Jean-Philippe Combal, Pharm.D., Ph.D., Vivet co-founder and CEO, noted, Early results from preclinical studies with VTX801 are very promising, and we are now well funded to advance this candidate into the clinic, while developing our portfolio and technologies."

Vivet's co-founders includeCombal (ex-Gensight Biologics, Sanofi),Jens Kurth, Ph.D. (ex-Anokion, Novartis), and Gloria Gonzlez-Aseguinolaza, Ph.D. (CIMA, University of Navarra).On announcement of Series A fundraising, Gloria Gonzlez-Aseguinolaza, Vivet CSO, said, By collaborating with leading institutions such as CIMA in Spain and MEE in the United States, Vivet has secured superior and novel gene therapy technologies and liver disease expertise. We believe these capabilities, combined with the international development expertise of the management team, create a company with very exciting prospects."

Read this article:
Vivet Raises 37.5M to Develop Gene Therapies for Rare Liver Diseases - Genetic Engineering & Biotechnology News

Recommendation and review posted by Bethany Smith

In recent years was proved that the best technique in the investigation of malignant lymphocytes is the. Fluorescence in situ hybridization (FISH). In the literature it was registered, in previous years, on an international study, conducted on 109 cases of CLL, 79 cases (72.5%) who had more genetic abnormalities: the remaining 30 cases (27.5%) had normal results, using FISH. The presence of del(11q), del(17p), mutated TP53, and unmutated IGHV typically predict for poor survival. Genetic Events in Chronic Lymphocytic Leukemia

In the normal cells, suppressor P-53 gene, coding proteins that bind to DNA and regulate the expression of genes, prevents the genome mutations. A mutation of the gene P-53 will inevitably lead to a process of carcinogenesis in which the cell divides endlessly. In recent years was proved that the best technique in the investigation of malignant lymphocytes, in the processes of deletions and rearrangements of chromosome genes, is the Florescence in situ Hybridization, (FISH) technique and this method is used as an alternative to chromosomal banding, a conventional application in molecular medicine, (Nelson BP et al, 2007).

In the literature of field in molecular medicine, it was registered, in previous years, on an international study, conducted on 109 cases of CLL, 79 cases (72.5%) who had more genetic abnormalities of p53 gene; the remaining 30 cases (27.5%) had normal results, using the same technique, FISH. The majority of patients, 67% (53.79) had a single anomaly and the remaining 33% had two or three genetic abnormalities. The chromosomes 14q32-17p translocation in LLC genome, which appeared similar to some common, had demonstrated abnormalities involving IGH gene, located on chromosome14q32, (Zerdoumi A et al, 2015).

Identification of P53 gene mutations in regions of 17 chromosome of hematological neoplasm is important because these mutations have an impact on the clinical course of patients and requires an attitude adjustment therapeutic adequate. Restoring function to p53 can induce lymphoma, apoptosis. Recent, endogenous somatic gene therapy research is a basic of trial clinical and therapeutic trial.

The DNA, (either integrated into the genome or episome external plasmid) is used to treat a disease arising as a result of mutations in chromosomal regions. In the past few years, this method has been included in the treatment of CLL, acute lymphocytic leukemia, [ALL], or multiple myeloma [MM], (Jump up^ "Gene Therapy". ama-assn.org. 4 April 2014. Retrieved22 March 2015).

The frequencies of P53 gene mutations in CLL can be categorized as individual biomarkers in proteomic and genomic profile for this type of leukemia that can be implemented in targeted patient treatment, within personalized medicine. Keywords: Gene P53, Chronic Lymphocytic Leukemia, Apoptosis, Fluorescence in situ Hybridization, Cancer. Conference: International Symposium on Clinical Neuroscience: Clinical Neuroscience for Optimization of Human Function, Orlando, USA, 7 Oct - 9 Oct, 2016. Presentation Type: Poster Presentation Topic: Abstracts ISCN 2016 Citation: UDRISTIOIU A (2016). Role of P53 gene in oncogenenesis of Chronic Lymphocytic Leukemia. Front. Neurol. Conference Abstract: International Symposium on Clinical Neuroscience: Clinical Neuroscience for Optimization of Human Function. doi: 10.3389/conf.fneur.2016.59.00101 Received: 01 May 2016; Published Online: 07 Sep 2016. * Correspondence: AURELIAN UDRISTIOIU, Emergency County Hospital Targu Jiu, Clinical Laboratory, Targu Jiu, Romania, aurelianu2007@yahoo.com

Follow this link:
Genetic Events in Chronic Lymphocytic Leukemia - Cordis News

Recommendation and review posted by simmons

The HIV virus is adeptat evading our best efforts to flushit from the human body, hence the lack of a cure, butanew study suggests thatthis feat may one day be possible. Researchers showed they were able to eliminate HIV from infected cells in animals using the powerful gene-editing tool, CRISPR/Cas9.

In the study, now published online in Molecular Therapy, scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) and the University of Pittsburgh succeeded in removing HIV DNA from the genomes of living animals a major step toward a cure, they said. The team used CRISPR gene-editing technology to remove HIV from the DNA of three different animalmodels, including a mouse that was transplanted with a humanized immune system.

Read: HIV Cure 2017? New Research Suggests Way To Theoretically Eliminate Virus From Body

"We confirmed the data from our previous work and have improved the efficiency of our gene editing strategy, said lead researcherWenhui Hu, in a recent statement. We also show that the strategy is effective in two additional mouse models, one representing acute infection in mouse cells and the other representing chronic, or latent, infection in human cells."

This breakthrough means that the team have begun to tackle a serious hurdle in the race to cure HIV. The next step would be to repeat the resultsin primatesto see if they are able to eliminate HIV DNA in latently infected T cells, and other HIV hideouts such as brain cells.

Science continues to advance more effective ways to target HIV, bringing us closer to a cure. Photo Courtesy of Pixabay

"Our eventual goal is a clinical trial in human patients, said study co-author Dr. Kamel Khalili in a recent statement.

For the study, the team built on previous proof-of-concept research from 2016 that demonstrated the ability to target and remove fragments of HIV from the genome of most tissues in experimental animals. Now, the team has taken this a step further, removing the latent HIV from DNA from the tissues of living animals. In order to measure the success of of their attempt, the team used a live bioluminescence imaging system to measure levels of HIV RNA.

In its latent form, the virus is able to lie dormant, meaning that it has stopped the production of new HIV cells, but can become reactivated at random, Aids Info reported. However, when HIV-infected cells are not actively producing the virus, HIV medication has no effect on them. This is what makes it especially difficult to completely flush the virus out of the body. According to Aids Info, finding ways to target and destroy these latent reservoirs of HIV are critical to figuring out a way to clear the virus from the body, and gene therapy is at the forefront of this search. In gene therapy treatments, such as that done in this study, scientists manipulate genes in order to either cut out or deactivate HIV in infected immune cells.

Source: Yin C, Zhang T, Qu X, et al. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Molecular Therapy. 2017

See Also:

HIV Breakthrough 2017: Treatment May Replace Need For Daily ART Medications, Leaves 5 Patients With Undetectable Virus Levels

HIV Breakthrough 2017: Scientists Find Protein Marker To Identify Dormant Virus-Infected Cells

See the rest here:
HIV Cure Research 2017: Gene Editing Tool CRISPR Cas9 Eliminated HIV In Animals - Medical Daily

Recommendation and review posted by simmons

Dimension Therapeutics Inc (DMTX) Upgraded at Zacks Investment ... The Cerbat Gem Dimension Therapeutics Inc (NASDAQ:DMTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to ... Dimension Therapeutics Inc (DMTX) Upgraded to Buy by Zacks ...Transcript Daily all 8 news articles »

Read the original:
Dimension Therapeutics Inc (DMTX) Upgraded at Zacks Investment ... - The Cerbat Gem

Recommendation and review posted by simmons

Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Prolactinoma written for patients

Hypopituitarism is the inability of the pituitary gland to provide sufficient hormones, due to an inability of the pituitary gland to produce hormones or due to an insufficient supply of hypothalamic-releasing hormones.

Symptoms depend on the degree of hormone depletion and the rapidity of onset. Hypopituitarism is usually a mixture of several hormonal deficiencies but rarely involves all the pituitary hormones. Hypopituitarism is usually chronic and lifelong, unless successful surgery or medical treatment of the underlying disorder can restore pituitary function.[1]

Taken from the results of one study:[1]

The most common cause of hypopituitarism is anterior pituitary tumours. The causes of hypopituitarism include:

See also the separate article on Pituitary Function Tests.

Hypopituitarism is sometimes associated with diabetes mellitus, dyslipidaemia, cardiovascular disease and osteoporosis.[1]

Patient Pro App Immediate reference All leaflets, without any ads Download

View post:
Hypopituitarism. Medical information about Hypopituitarism ...

Recommendation and review posted by Bethany Smith

Interested participants and investors may access the conference call by dialing either:

1 (855) 656-0926 (U.S.)

1 (412) 542-4198 (international)

The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days.

A replay of the call will be available for seven days. Access the replay by calling 1 (877) 344-7529 (U.S.) or 1 (412) 317-0088 (international) and using the replay access code 10106783.

About Aytu BioScience

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The company currently markets two products in the U.S.: Natesto, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets. For more information visit aytubio.com.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks relating to gaining market acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaborations. We also refer you to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc.'s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Investors:

Amato and Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aytu-bioscience-to-provide-fiscal-third-quarter-2017-business-update-300450288.html

SOURCE Aytu BioScience, Inc.

Home

Read this article:
Aytu BioScience to Provide Fiscal Third Quarter 2017 Business Update - PR Newswire (press release)

Recommendation and review posted by sam

Aqua Botanical Stem Cell Therapy

Ethical concerns have slowed embryonic medical research into applications for stem cells. Also, the embryonic stem cells can unpredictably cause cancer in the treated patient.

New research demonstrate that Stem cell nutrition dereived from aqua botanical source supports the natural role of adult stem cells. These plant stem cell extracts are typically derived from certain edible algae that grows in fresh water.

When there is an injury or a stress to an organ, compounds are released that reach the bone marrow and trigger the release of stem cells. Stem Cells can be thought of as master cells. Stem cells circulate and function to replace dysfunctional cells, thus fulfilling the natural process of maintaining optimal health

Dr. Robert Sampson, MD on stem cell nutrition - "... we have a product that has been shown and demonstrated in the patent to increase the level of adult circulating stem cells by up to 30%. It seems to me we're having a great opportunity here to optimize the body's natural ability to create health."

Stem cell nutrition are typically aquatic botanicals and support wellness by assisting the body in its ability to maintain healthy stem cell physiology, production, and placement. Just as antioxidants are important to protect your cells from free radical damage, stem cell nutrition is equally important to support your stem cells in maintaining proper organ and tissue functioning in your body.

The health benefits of having more stem cells in the blood circulation have been demonstrated by numerous scientific studies. It would be too long here to summarize this vast body of scientific data. I simply suggest you research the work of Dr. Donald Orlic at the National Institute of Health.

The theory that Adult Stem Cells are nothing less than the human body's natural self-renewal system has profound implications for every area of modern medicine. The idea that heart disease, diabetes, liver degeneration, and other conditions could be things of the past is no longer science fiction; because of recent Adult Stem Cell research breakthroughs, these are real possibilities in the short term.

Stem cells are defined as cells with the unique capacity to self-replicate throughout the entire life of an organism and to differentiate into cells of various tissues. Most cells of the body are specialized and play a well-defined role in the body. For example, brain cells respond to electrical signals from other brain cells and release neurotransmitters; cells of the retina are activated by light, and pancreatic -cells produce insulin. These cells, called somatic cells, will never differentiate into other types of cells or even proliferate. By contrast, stem cells are primitive cells that remain undifferentiated until they receive a signal prompting them to become various types of specialized cells.

Dr. Cliff Minter - "Stem cells are the most powerful cells in the body. We know that stem cells, once they're circulating in the bloodstream, will travel to any area of the body that has been compromised or damaged and turn into healthy cells. There have been controversial discussions about the new stem cells found in embryos, but the truth is that everyone has adult stem cells in their own bodies. We are all created from stem cells.

As a child or a young adult, your body automatically releases stem cells whenever you injure yourself. That's why you heal so fast when you are younger. After about age 35, we don't heal as fast anymore, because the stem cells aren't released the same way as when we are younger. Stem cell nutrition helps all of us heal our bodies. If you look at the New England Journal of Medicine, you'll find that the number one indicator of a healthy heart is the number of stem cells circulating in the body. Stem cell nutrition is the organic and all-natural way to stimulate the bone marrow to release adult stem cells into the bloodstream.

By taking stem cell nutrition, you can maintain optimum health and aid your body in healing itself. It's certainly a better way to recuperate from an illness than using prescription drugs, because even when a medication works, it can often be hard on your liver and the rest of your body. Stem cell nutrition has no negative side effects. This makes it a powerful approach to healing and good health in general.

I found out about stem cell nutrition after someone asked for my opinion on it. I did some research and found it to be one of the greatest ways to slow down aging that we have. Aging is nothing more than the breakdown of cells. Stem cell nutrition combats that action. As cells break down, stem cell nutrition replaces them with healthy cells. This is the greatest, most natural anti-aging method I know. I was skeptical at first, but the results I've personally seen in people I've talked with have been wide-ranged. Lots of people have reported an increase in energy and better sleeping patterns.

I've seen people with arthritis in various parts of their bodies reverse the disease, and people with asthma end up with their lungs totally clear. One person that was on oxygen almost 24/7 is now totally off of oxygen. Two ladies who suffered badly from PMS told me they were 100 percent symptom-free within weeks of starting the stem cell nutrition. Two people I know had tennis elbow which usually takes about six to nine months to heal. Within weeks of taking stem cell nutrition, both report their "tennis elbow" is gone. It makes sense, because stem cells go to whatever area is compromised and turn into healthy cells.

I use stem cell nutrition as a preventative. I've noticed an increase in my energy level and an improved sleeping pattern. Stem cell nutrition has zero negative side effects, is very powerful, and we know how it works. It's good for children as well as adults. This is the best, most natural way I know to optimum health. If you just want to use it for prevention, this is the best thing I know for staying healthy. And if you do those and regaining optimum health. I recommend it to everybody."

Dr. Cliff Minter (retired) graduated from Illinois College of Podiatric Medicine. He completed his residency at the Hugar Surgery Center in the Hines Veteran Administration Hospital in Illinois before going into private practice in Ventura, CA. Dr. Minter is a national and international speaker on the subjects of business and nutritional products.

The Stem Cell Theory of Renewal proposes that stem cells are naturally released by the bone marrow and travel via the bloodstream toward tissues to promote the body's natural process of renewal. When an organ is subjected to a process that requires renewal, such as the natural aging process, this organ releases compounds that trigger the release of stem cells from the bone marrow. The organ also releases compounds that attracts stem cells to this organ. The released stem cells then follow the concentration gradient of these compounds and leave the blood circulation to migrate to the organ where they proliferate and differentiate into cells of this organ, supporting the natural process of renewal.

Most of the cells in the human body are specialists assigned to a specific organ or type of tissue, such as the neuronal cells that wire the brain and central nervous system. Stem cells are different. When they divide, they can produce either more stem cells, or they can serve as progenitors that differentiate into specialized cells as they mature. Hence the name, because specialist cells can "stem" from them. The potential to differentiate into specialist cells whose populations in the body have become critically depleted as the result of illness or injury is what makes stem cells so potentially valuable to medical research.

The idea is that if the fate of a batch of stem cells could be directed down specific pathways, they could be grown, harvested, and then transplanted into a problem area. If all went according to plan, these new cells would overcome damaged or diseased cells, leading to healing and recovery. "The life of a stem cell can be viewed as a hierarchical branching process, where the cell is faced with a series of fate switches," Schaffer says. "Our goal is to identify the cell fate switches, and then provide stem cells with the proper signals to guide them down a particular developmental trajectory."

Stem cells have the remarkable potential to develop into many different cell types in the body. Serving as a sort of repair system for the body, they can theoretically divide without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential to either remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

When a stem cell divides, each new cell has the potential to either remain a stem cell or become another type of cell with a more specialized function. Scientists believe it should be possible to harness this ability to turn stem cells into a super "repair kit" for the body.

Scientist and author Christian Drapeau explains how the Stem Cell enhancers function to maximize human performance - Supporting the release of stem cells from the bone marrow and increasing the number of circulating stem cells improves various aspects of human health. For very active and sports focused people, Stem Cells are the raw materials to repair micro-tears and micro-injuries created during training. The results, according to Drapeau, are that active people, whether former NBA stars or amateur weekenders, can exercise more intensely at each training session with the ultimate consequence of greater performance.

Theoretically, it should be possible to use stem cells to generate healthy tissue to replace that either damaged by trauma, or compromised by disease. Among the conditions which scientists believe may eventually be treated by stem cell therapy are Parkinson's disease, Alzheimer's disease, heart disease, stroke, arthritis, diabetes, burns and spinal cord damage.

Both of my big dogs have gained their youth back. I am a true believer in Stem Cell Nutrition for pets as it has provided a spectacular change in both Ginger and Rowdy. Sonya, IN

Stem cell nutrition for dogs, horses and other animals are specially formulated to be a delectable treat for your animal. The pet chewables and equine blends make it easy to provide your animals with this valuable nutritional supplement. The most common story is that of old, tired and sluggish dogs turned within a week or so into active, alert dogs running around like puppies. The same was observed in horses. Old horses who used to remain standing in the barn or under a tree, sluggish or stricken by too much discomfort to walk around, suddenly began moving about, and at times running and bucking like young colts. One of the most common reports was obvious improvements in hoof health and coat appearance.

times. When there is an injury or a stress to an organ of your beloved pet or horse, compounds are released that reach the bone marrow and trigger the release of stem cells. Stem Cells can be thought of as master cells. Stem cells circulate and function to replace dysfunctional cells, thus fulfilling the natural process of maintaining optimal health.

As they do in humans, adult stem cells reside in animals bone marrow, where they are released whenever there is a problem somewhere in the body. Looking back on stem cell research, we realize that most studies have been done with animals, mostly mice, but also with dogs, horses, pigs, sheep and cattle. These studies have revealed that animal stem cells conduct themselves the same way human stem cells do. When there is an injury or a stress to an organ of your beloved pet or horse, compounds are released that reach the bone marrow and trigger the release of stem cells. The stem cells then travel to tissues and organs in need of help to regain optimal health.

Eve-Marie Lucerne - Eve-Marie keeps nine horses, all older thoroughbreds, and was eager to participate in the trials of a new stem cell enhancer for horses. She shared her allotment of test products with a few large commercial thoroughbred farms, veterinarians and other horse people she knows, and has been pleased with the consistently excellent results she has seen and others have reported to her. This product will help so many animals, she says, adding, People and animals are more alike than we are different. So it makes sense that a stem cell enhancer for animals with promote their health, too.

Eve-Marie's Equine Stem Cells Nutrition show dramatic results. For several horses facing serious physical challenges, cases where the animals might have to be put down, we saw a return to quality of life. This did not happen before Equine Stem Cell Nutrition. Eve-Marie says that this turnaround was quick, less than two weeks in many cases, and that the subject horses were back to health and enjoying pasture life within a month. One of the unofficial trial subjects for the equine stem cell nutrition was a 30-year old donkey who was in bad shape, Eve-Marie reports. He hadchronic respiratory difficulty and could move about only haltingly. His owner had stem cell enhancer supplements to help with her own serious health challenges and shared it with the donkey. The donkey's owner says this is the first time she wasn't sick, and her donkey is walking all around, feeling great an enjoying life again!

Farrier and National Hoof practitioner Stephen Dick received some of the trial product from Eve-Marie, and had good results with the two horses he selected for trial. For a 12-year-old quarterhorse stallion, the equine product brought dramatic results. This horse used to lie down twenty-two hours of the day, because he suffered discomfort whenever he stood, Steve reports, continuing, after a couple of weeks with Equine Stem Cell Nutrition, he was getting up and moving around, showing no discomfort. For a high-spirited mare with a leg problem, the equine product brought about a whole new lease on life, Steve says. This horse had been in a stall for 8 months. After about 6 weeks taking the equine product with her grain, her condition had improved and she was out of the stall, walking around in the pasture again.

Little Joe, a small 18-year-old quarter horse that Judy Fisher bought when he was nearly 400 pounds underweight. You could count his ribs, Judy says, remembering, and his backbone stuck up like a ridge all along his back. He was very, very thin! Little Joe also suffered from breathing problems that kept him lethargic and inactive. Vet-recommended remedies were unsuccessful in changing Little Joe's physical problems, and the vet told Judy he didn't expect Little Joe to live through the winter. I figured Little Joe was in such bad shape that anything was worth a try, she says.

She began giving the horse stem cell nutrition with his feed and grain twice a day. Within a couple of weeks, Judy was surprised to see Little Joe beginning to gain weight and run, buck, snort and kick. His breathing was no longer labored and his skin and coat were improving. Within six weeks Little Joe's overall appearance had changed dramatically. He had put on almost 300 pounds. When his former owner came to visit, Judy says, he didn't recognize Little Joe. That's how different he looked!

Sara participated in the stem cell nutrition product trials with her two horses and her 80-pound mixed-breed dog. She noted significant improvement in the health and quality of life for all three animals during the time of the trials. For JJ, Sara's 18-year old quarterhorse, the equine product brought about improvements in his overall mood, appearance and alertness quickly. He really liked the product from the beginning, Sara reports, pointing out that Hank, her 16-year-old thoroughbred/quarterhorse, had not taken to the taste of it too readily. I was able to slowly wean him on it though, she says. For Hank, the equine product was a balm for the skin problems resulting from his allergy to fly bites.

His skin condition improved dramatically. Sara reports, noting that before the equine product the horse had scratched and bitten himself into ope wounds; after the equine product, the scratching and biting dropped off to almost nothing. Sara also noticed an increase in Hank's energy and liveliness in the first week on the equine product. The horse's foot and hip discomforts also responded well, leading to a noticeable increase in his mobility and an overall improvement in his quality of life throughout the two-month study.

Sara gave the pet product to her dog, Roxy, who had suffered for two years with ear problems that led to scratching, often until her skin was raw. Vet-recommended remedies had been temporary, quick-fixes, Sara says, but the discomfort always returned with a vengeance. For the pet trials, Sara gave Roxy two tabs of the product a day for two months, noting this is the only supplement she was getting. Sara says Roxy's problem with her ears definitely improved, the hair as grown back on her head and ears, and the ear problem has not recurred, adding that Roxy is happier and engaging, more playful.

The National Health Institute lists seventy-four treatable diseases using ASCs in therapy - an invasive and costly procedure of removing the stem cells from one's bone marrow (or a donor's bone marrow) and re-injecting these same cells into an area undergoing treatment. For example, this procedure is sometimes done before a cancer patient undergoes radiation. Healthy stem cells from the bone marrow are removed and stored, only to be re-inserted after radiation into the area of the body in need of repair. This is a complex and expensive procedure, not accessible to the average person. However, there is now a way that every single person, no matter what their health condition, can have access to the benefits of naturally supporting their body's innate ability to repair every organ and tissue using stem cell nutrition.

David A. Prentice, Ph.D. - "Within just a few years, the possibility that the human body contains cells that can repair and regenerate damaged and diseased tissue has gone from an unlikely proposition to a virtual certainty. Adult stem cells have been isolated from numerous adult tissues, umbilical cord, and other non-embryonic sources, and have demonstrated a surprising ability for transformation into other tissue and cell types and for repair of damaged tissues.

A new U.S. study involving mice suggests the brain's own stem cells may have the ability to restore memory after an injury. These neural stem cells work by protecting existing cells and promoting neuronal connections. In their experiments, a team at the University of California, Irvine,were able to bring the rodents' memory back to healthy levels up to three months after treatment. The finding could open new doors for treatment of brain injury, stroke and dementia, experts say.

"This is one of the first reports that you can take a stem cell transplantation approach and restore memory," said lead researcher Mathew Blurton-Jones, a postdoctorate fellow at the university. "There is a lot of awareness that stem cells might be useful in treating diseases that cause loss of motor function, but this study shows that they might benefit memory in stroke or traumatic brain injury, and potentially Alzheimer's disease."

In the study, published in the Oct. 31 issue of the Journal of Neuroscience, Blurton-Jones and his colleagues used genetically engineered mice that naturally develop brain lesions. The researchers destroyed cells in a brain area called the hippocampus. These cells are known to be vital to memory formation and it is in this region that neurons often die after injury, the researchers explained. To test the mice's memory, Blurton-Jones's group conducted place and object recognition tests with both healthy mice and brain-injured mice.

Healthy mice remembered their surroundings about 70 percent of the time, while brain-injured mice remembered it only 40 percent of the time. For objects, healthy mice recalled objects about 80 percent of the time, but injured mice remembered them only 65 percent of the time. The researchers then injected each mouse with about 200,000 neural stem cells. They found that mice with brain injuries that received the stem cells now remembered their surroundings about 70 percent of the time -- the same as healthy mice. However, mice that didn't receive stem cells still had memory deficits.

The researchers also found that in healthy mice injected with stem cells, the stem cells traveled throughout the brain. In contrast, stem cells given to injured mice lingered in the hippocampus. Only about 4 percent of those stem cells became neurons, indicating that the stem cells were repairing existing cells to improve memory, rather than replacing the dead brain cells, Blurton-Jones's team noted. The researchers are presently doing another study with mice stricken with Alzheimer's. "The initial results are promising," Blurton-Jones said. "This has a huge potential, but we have to be cautious about not rushing into the clinic too early."

One expert is optimistic about the findings. "Putting in these stem cells could eventually help in age-related memory decline," said Dr. Paul R. Sanberg, director of the Center of Excellence for Aging and Brain Repair at the University of South Florida College of Medicine. "There is clearly a therapeutic potential to this." Sanberg noted that for the process to work with Alzheimer's it has to work with older brains. "There is clearly therapeutic potential in humans, but there are a lot of hurdles to overcome," he said. "This is another demonstration of the potential for neural stem cells in brain disorders.".

Dr. Nancy White Ph.D.- " I've always been interested in health generally and in particular the brain, focusing on the balance of neurotransmitters. I often do quantitative EEG's for assessment of my patients. I'm impressed with the concept of a natural product like stem cell nutrition that could help release adult stem cells from the bone mass where the body would have no objection and no rejection. I've tried stem cell nutrition for general health anti-aging. After taking it for a time, I fell more agile and my joints are far more flexible. I was astounded while doing yoga that I was suddenly able to bend over and touch my forehead to my knees. I haven't been able to do that comfortably in probably twenty years. I noticed how much better my balance has become. I believe stem cell nutrition is responsible for these effects, because I certainly haven't been trained extensively in yoga. Also since taking stem cell nutrition, I feel better and my skin is more moist and has a finer texture.

A bald friend of mine, who is also taking the stem cell nutrition, had several small cancers on top of his head. His doctor had removed one from his arm already, and his dermatologist set a date to remove those from his scalp. Before the appointment, my friend was shaving one morning and, looking in the mirror, saw that the cancers were all gone. They had disappeared within a few weeks of starting the stem cell nutrition and his skin is better overall. Also, his knee, which he'd strained playing tennis, was like new. Stem cell nutrition seems to go where the body's priority is. You never know what the affect is going to be, but you notice something is changing. Another friend of mine seems to be dropping years. Her skin looks smoother and her face younger. After about six weeks on the stem cell nutrition, she looks like she's ten years younger. A woman who gives her regular facials asked what she was doing, because her skin looked so much different. Stem cell nutrition is remarkable and could help anybody. Everybody should try it, because it's natural and there are no risks. As we grow older in years, we still can have good health. That's the ideal. Even if you don't currently have a problem, stem cell nutrition is a preventative." Dr. White holds a Ph. D. in Clinical Psychology, an MA in Behavioral Science, and a B.F.A. in Fine Arts, Magna Cum Laude. In addition, she is licensed in the State of Texas as a Psychologist , a Marriage and Family Therapist and as a Chemical Dependency Counselor.

Fernando Aguila, M.D. - "Due to a heavy patient load, I have recently found that I tire more easily, my legs are cramping, and by the time I get home, even my shoulders and rib cage hurt. I knew I had to find a way to increase my stamina, energy and vitality. A friend gave me information about stem cell nutrition and how it promotes the release of stem cells in the body. One of the components apparently promotes the migration of the stem cells to tissues or organs where regeneration and repair is needed most. My attention was drawn to the fact that it can increase energy, vitality, wellness, concentration, and much more. It sounded just like what I needed. Since then, I've heard reports of people experiencing excellent results in a number of different areas in their health. The improvements sounded dramatic. Because of all of their testimonies, I was willing to believe it could promote wellness in the human body.

I tried stem cell nutrition myself. After a day, of hard work, I realized I wasn't tired at all, my legs were not aching, and I didn't have any shoulder pain. I decided the stem cell nutrition must be working. I continued to take it, and was able to work so efficiently and steadily that one surgeon commented that I was moving like a ball of fire. Stem cell nutrition gives me support physically and mentally. I look forward to seeing what the major medical journals have to say about the studies being done with this new approach to wellness." Fernando Aguila, M.D., graduated from the University of Santa Thomas in Manila , Philippines. He finished his internship at Cambridge City Hospital, Cambridge, MA and completed his residency at the New England Medical Center in Boston, MA. He obtained a fellowship in OB-GYN anesthesia at the Brigham and Women's Hospital in Boston and a fellowship in cardio-thoracic anesthesia at the Cleveland Clinic Foundation in Cleveland, OH.

Christian Drapeau is America's best known advocate for Adult Stem Cell science health applications and the founder of the field of Stem Cell Nutrition. He holds a BS in Neurophysiology from McGill University and a Master of Science in Neurology and Neurosurgery from the Montreal Neurological Institute.

One particular stem cell enhancers that was studied was found to contain a polysaccharide fraction that was shown to stimulate the migration of Natural Killer (NK) cells out of the blood into tissues. The same polysaccharide fraction was also shown to strongly stimulate the activation of NK cells. NK cells play the very important role in the body of identifying aberrant or defective cells and eliminating them. NK cells are especially known for their ability to detect and destroy virally infected cells and cells undergoing uncontrolled cellular division. The same polysaccharide fraction was also shown to stimulate macrophage activity. Macrophages constitute the front line of the immune system. They first detect an infection or the presence of bacteria or virally infected cells, and they then call for a full immune response. Adult Stem Cell Nutritional Enhancer also contains a significant concentration of chlorophyll and phycocyanin, the blue pigment in AFA. Phycocyanin has strong anti-inflammatory properties and therefore can assist the immune system.

The release of stem cells from the bone marrow and their migration to tissues is a natural process that happens everyday. Stem cell enhancers simply support that natural process and tips the balance toward health everyday. It does not do anything that the body does not already do everyday. So far, no instances of cancer or any similar problem have ever been observed when using in vivo natural release of stem cells from the bone marrow.

Each day, stem cells in the bone marrow evolve to produce red blood cells, white blood cells, and platelets. These mature cells are then released into the bloodstream where they perform their vital life-supporting functions. When bone marrow stem cell activity is interfered with, diseases such as anemia (red blood cell deficit), neutropenia (specialized white blood cell deficit), or thrombocytopenia (platelet deficit) are often diagnosed. Any one of these conditions can cause death if not corrected.

Scientists have long known that folic acid, vitamin B12, and iron are required for bone marrow stem cells to differentiate into mature red blood cells.3-7 Vitamin D has been shown to be crucial in the formation of immune cells,8-11 whereas carnosine has demonstrated a remarkable ability to rejuvenate cells approaching senescence and extend cellular life span.12-28

Other studies of foods such as blueberries show this fruit can prevent and even reverse cell functions that decline as a result of normal aging.29-36 Blueberry extract has been shown to increase neurogenesis in the aged rat brain.37,38 Green tea compounds have been shown to inhibit the growth of tumor cells, while possibly providing protection against normal cellular aging.39,40

Based on these findings, scientists are now speculating that certain nutrients could play important roles in maintaining the healthy renewal of replacement stem cells in the brain, blood, and other tissues. It may be possible, according to these scientists, to use certain nutrient combinations in the treatment of conditions that warrant stem cell replacement

These studies demonstrate for the first time that various natural compounds can promote the proliferation of human bone marrow cells and human stem cells. While these studies were done in vitro, they provide evidence that readily available nutrients may confer a protective effect against today's epidemic of age-related bone marrow degeneration.

Dr. Robert Sampson, MD on stem cell nutrition - "... we have a product that has been shown and demonstrated in the patent to increase the level of adult circulating stem cells by up to 30%. It seems to me we're having a great opportunity here to optimize the body's natural ability to create health." Recent scientific developments have revealed that stem cells derived from the bone marrow, travel throughout the body, and act to support optimal organ and tissue function. Stem cell enhancers supports the natural role of adult stem cells. Stem cell enhancer are typically derived from certain edible algae that grows in fresh water.

The possibility that a decline in the numbers or plasticity of stem cell populations contributes to aging and age-related disease is suggested by recent findings. The remarkable plasticity of stem cells suggests that endogenous or transplanted stem cells can be tweaked' in ways that will allow them to replace lost or dysfunctional cell populations in diseases ranging from neurodegenerative and hematopoietic disorders to diabetes and cardiovascular disease.

As you age, the number and quality of stem cells that circulate in your body gradually decrease, leaving your body more susceptible to injury and other age-related health challenges. Just as antioxidants are important to protect your cells from free radical damage, stem cell nutrition is equally important to support your stem cells in maintaining proper organ and tissue functioning in your body.

A fundamental breakthrough in our understanding of nervous system development was the identification of multipotent neural stem cells (neurospheres) about ten years ago. Dr. Weiss and colleagues showed that EGF (epidermal growth factor) dependent stem cells could be harvested from different brain regions at different developmental stages and that these could be maintained over multiple passages in vitro. This initial finding has lead to an explosion of research on stem cells, their role in normal development and their potential therapeutic uses. Many investigators have entered this field and the progress made has been astounding.

How does an increase in the number of circulating stem cells lead to optimal health? Circulating stem cells can reach various organs and become cells of that organ, helping such organ regain and maintain optimal health. Recent studies have suggested that the number of circulating stem cells is a key factor; the higher the number of circulating stem cells the greater is the ability of the body at healing itself. Scientific interest in adult stem cells has centered on their ability to divide or self-renew indefinitely, and generate all the cell types of the organ from which they originate, potentially regenerating the entire organ from a few cells. Adult stem cells are already being used clinically to treat many diseases. These include as reparative treatments with various cancers, autoimmune disease such as multiple sclerosis, lupus and arthritis, anemias including sickle cells anemia and immunodeficiencies. Adult stem cells are also being used to treat patients by formation of cartilage, growing new corneas to restore sight to blind patients, treatments for stroke, and several groups are using adult stem cells to repair damage after heart attacks. Early clinical trials have shown initial success in patient treatments for Parkinsons disease and spinal cord injury. The first FDA approved trial to treat juvenile diabetes in human patients is ready to begin at Harvard Medical School, using adult stem cells. An advantage of using adult stem cells is that in most cases, the patients own stem cells can be used for the treatment, circumventing the problems of immune rejection, and without tumor formation.

Why do we hear much in the news about embryonic stem cells and very little about adult stem cells? The first human embryonic stem cells were grown in vitro, in a petri dish, in the mid 1990s. Rapidly, scientists were successful at growing them for many generations and to trigger their differentiation into virtually any kind of cells, i.e. brain cells, heart cells, liver cells, bone cells, pancreatic cells, etc. When scientists tried growing adult stem cells, the endeavor was met with less success, as adult stem cells were difficult to grow in vitro for more than a few generations. This led to the idea that embryonic stem cells have more potential than adult stem cells. In addition, the ethical concerns linked to the use of embryonic stem cells have led to a disproportionate representation of embryonic stem cells in the media. But recent developments over the past 2-3 years have established that adult stem cells have capabilities comparable to embryonic stem cells in the human body, not in the test tube. Many studies have indicated that simply releasing stem cells from the bone marrow can help support the body's natural process for renewal of tissues and organs.

The bone marrow constantly produces stem cells for the entire life of an individual. Stem cells released by the bone marrow are responsible for the constant renewal of red blood cells and lymphocytes (immune cells). A 25-30% increase in the number of circulating stem cells is well within physiological range and does not constitute stress on the bone marrow environment. The amount of active bone marrow amounts to about 2,600 g (5.7 lbs), with about 1.5 trillion marrow cells. Stem cells that do not reach any tissue or become blood cells return to the bone marrow.

Effectiveness of stem cell "enhancers" was demonstrated in a triple-blind study. Volunteers rested for one hour before establishing baseline levels. After the first blood samples, volunteers were given stem cell "enhancers"or placebo. Thereafter, blood samples were taken at 30, 60 and 120 minutes after taking the consumables. The number of circulating stem cells was quantified by analyzing the blood samples using Fluorescence-Activated Cell Sorting (FACS). Consumption of stem cell "enhancers" triggered a significant 25-30% increase in the number of circulating stem cells.

Continue reading here:
stem cells - Shirley's Wellness Cafe

Recommendation and review posted by simmons

Space | Publishing | Funding | Conservation | Politics | Policy | People | Trend watch | Coming up

Cassini catches new views of Saturn NASAs Cassini spacecraft plunged between Saturn and its rings on 26 April, beginning the final stages of its 20-year mission. At its closest, Cassini whizzed just 300 kilometres from the innermost visible edge of Saturns rings and 3,000kilometres above the top of the planets clouds. The images sent back include this close-up shot of Saturns surface. The spacecraft is exploring this never-before-visited region of the Solar System on its way to a final plunge into Saturns atmosphere in September.

NASA/JPL-Caltech/Space Science Inst.

Physics for all Particle physicists will soon be able to publish open-access papers in three journals of the American Physical Society (APS), including Physical Review Letters, free of charge. The deal, announced on 27April, was struck between the APS and CERN, the European particle-physics laboratory in Switzerland. From January 2018, high-energy physics research done anywhere in the world will be able to be published open-access in the journals, and at no direct cost. Publication fees will be covered by the Sponsoring Consortium for Open Access Publishing in Particle Physics (SCOAP3), an international partnership set up in 2012 that is funded in large part by libraries. CERNs Large Hadron Collider already had an open-access agreement with the APS.

Cash boost BioRxiv, a free online archive for draft versions of biology research papers, is to receive a windfall from the philanthropic Chan Zuckerberg Initiative (CZI), founded by Facebook co-founder Mark Zuckerberg and his physician wife Priscilla Chan. On 26April, the initiative announced a multi-year funding package the terms of which have not been disclosed for expanding the popular preprint server, which posted its 10,000th manuscript last month. The new money will pay for staff and technology development at bioRxiv, says John Inglis, the executive director of Cold Spring Harbor Laboratory Press and co-founder of the 3-year-old site.

Poor protection A cross-party group of UK politicians has rebuked the countrys government over its ocean-protection record. In a report released on 25April, the Environmental Audit Committee says marine protected areas around the coasts of the British Isles are not managed properly and that vulnerable sites and species are not suitably protected. The committee says it is also shocked and disappointed that the government will not be creating reference sites to help gauge the success of the network of protected areas. Only 50marine conservation zones have been created in British waters, whereas 127 were recommended in 2011.

Legal concerns Hungarys revised higher-education law is incompatible with internal market freedoms and the right of academic freedom in the European Union (EU), the European Commission said on 26 April. The contentious law, which was passed by the Hungarian parliament on 4 April, bars international universities from operating in Hungary unless they have a campus in their home country. The commission sent Budapest a letter of formal notice, outlining legal concerns, to which the Hungarian government has one month to respond. Speaking in the European Parliament on 26 April, Hungarys Prime Minister Viktor Orbn rejected accusations that the law would specifically target the Central European University in Budapest.

Eric Vidal/Reuters

Hungarys Prime Minister Viktor Orbn.

UK research reform On 27April, the British parliament approved a controversial package of reforms to the organization of UK research and universities. Nine research-funding agencies, including Britains seven research councils, will now be merged into a new body, called UK Research and Innovation. The organization will oversee annual spending of more than 6billion (US$7.8 billion). Parliaments unelected upper chamber, the House of Lords, had forced the government into a number of compromises in the reform, including safeguards for institutional autonomy and the independence of research funding from political interference.

Stem-cell payout Allegations of fraud at a US stem-cell laboratory have led to an order for Partners HealthCare System and Brigham and Womens Hospital (BWH) of Boston, Massachusetts, to pay US$10million to the government. The settlement, announced by the US Department of Justice on 27April, came in response to charges that the laboratory of former BWH researcher Piero Anversa used manipulated and falsified data about his research involving cardiac stem cells in applications for federal research funds. Anversa and a colleague sued the hospital in 2014, charging that its investigation of the allegations had damaged their careers. That lawsuit was dismissed.

Offshore drilling President Donald Trump has asked the US Department of the Interior to reopen Arctic federal waters for oil and gas drilling. On 28April, Trump signed an executive order to lift restrictions on offshore mineral exploration in the Beaufort and Chukchi seas. The controls had been imposed by Barack Obamas administration in response to environmental concerns. The order also asks for a review of the five-year plan to sell oil and gas leases in parts of the Gulf of Mexico and Atlantic Ocean areas that the previous administration had closed to offshore exploration and development.

Fishy results Swedens Central Ethical Review Board has ruled that two researchers at Uppsala University have been guilty of scientific dishonesty in relation to a study published last year in Science (O. M. Lnnstedt and P. Eklv Science 352, 12131216; 2016). The board says that the paper by Oona Lnnstedt and Peter Eklv on the claimed harmful impact of microplastics on certain fish larvae should be withdrawn. Uppsala University says it will consider this report alongside an earlier report conducted by the university itself, which found no misconduct.

Leadership row Cell biologist Mary Beckerle has been invited to return to her position as head of the Huntsman Cancer Institute, housed at the University of Utah in Salt Lake City but mainly funded by billionaire Jon Huntsman. Last month, Vivian Lee, dean of the universitys school of medicine and senior vice-president for health sciences, fired Beckerle for undisclosed reasons. In response, institute staff raised protests and Huntsman threatened to revoke a planned donation. Following Beckerles reinstatement on 25 April, Huntsman released a statement pledging US$120million to the institute. On 28 April, Vivian Lee resigned from her leadership positions.

Preventive arrest Stem-cell maverick Davide Vannoni was arrested in Turin, Italy, on 26April after police phone taps indicated that he was seeking new foreign locations to continue his outlawed therapy, according to news reports. Vannoni had been sentenced to jail for conspiracy and fraud for administering unproven stem-cell therapy in Italy to people with incurable diseases through his Stamina Foundation. The sentence was suspended in March last year in a plea bargainon the condition that he cease offering the treatment. Vannoni continued treating people in the Republic of Georgia until the government there banned him in December.

Physicist fired Physicist Etienne Klein has been sacked as president of the Institute for Advanced Studies for Science and Technology (IHEST) in Paris following a series of allegations of plagiarism in his articles and books for the general public. Kleins dismissal was announced in the French governments official journal on 28April. He is replaced by Antoine Petit, head of INRIA, Frances national computer-science agency.

The Arctic is warming more than twice as fast as the rest of the planet. A report by the Arctic Monitoring and Assessment Programme finds that the region was warmer between 2011 and 2014 than at any time since records began around 1900. The rapid warming is hastening the melting of glaciers and sea ice, and boosting sea-level rise. The extent of snow cover across the Arctic regions of North America and Eurasia each June has halved compared with observations before 2000, the report finds.

Source: Snow, Water, Ice, and Permafrost in the Arctic

818 May Details of the Paris climate agreement are negotiated at a United Nations climate-change conference in Bonn, Germany.

89 May Scientists discuss trends in genome editing at a CRISPR congress in London.

913 May The annual Biology of Genomes meeting takes place in Cold Spring Harbor, New York.

Read more from the original source:
Arctic drilling, controversial reforms and new views of Saturn - Nature.com

Recommendation and review posted by simmons

StockNewsUnion

US Stem Cell Inc (OTCMKTS:USRM) Receives Institutional Fund ... StockNewsUnion US Stem Cell Inc (OTCMKTS:USRM) is a biotechnology company that was formerly known as Bioheart, Inc. US Stem Cell, headquartered in Sunrise, FL, seeks ... and more »

View original post here:
US Stem Cell Inc (OTCMKTS:USRM) Receives Institutional Fund ... - StockNewsUnion

Recommendation and review posted by simmons